Literature DB >> 30880589

Genetic polymorphisms in CDH1 and Exo1 genes elevate the prostate cancer risk in Bangladeshi population.

Hasnain Imtiaz1, Sharmin Afroz1, Md Amir Hossain2, Sm Faysal Bellah3, Md Mostafizur Rahman1, Md Shahin Kadir1, Razia Sultana4, Md Abdul Mazid5, Md Mustafizur Rahman1.   

Abstract

The polymorphisms of invasion suppressor gene CDH1 and DNA mismatch repair gene Exo1 have been reported to play critical role in the development, tumorigenesis, and progression of several kinds of cancers including prostate cancer. This study was designed to analyze the contribution of single-nucleotide polymorphisms of the CDH1 (-160C/A) and Exo1 (K589E) to prostate cancer susceptibility in Bangladeshi population. The study included 100 prostate cancer cases and age-matched 100 healthy controls. Polymerase chain reaction-restriction fragment length polymorphism analysis was used to determine the genetic polymorphisms. A significant association was found between CDH1 -160C/A (rs16260) and Exo1 (rs1047840, K589E) polymorphisms and prostate cancer risk. In case of CDH1 -160C/A polymorphism, the frequencies of the three genotypes C/C,C/A, and A/A were 45%, 48%, and 7% in cases and 63%, 32%, and 5% in controls, respectively. The heterozygote C/A genotype and combined C/A + A/A genotypes showed 2.10-fold (odds ratio = 2.1000, 95% confidence interval = 1.2956-4.0905, p = 0.013) and 2.08-fold (odds ratio = 2.0811, 95% confidence interval = 1.1820-3.6641, p = 0.011) increased risk of prostate cancer, respectively, when compared with homozygous C/C genotypes. The variant A allele also was associated with increased risk of prostate cancer (odds ratio = 1.6901, 95% confidence interval = 1.0740-2.6597, p = 0.0233). In case of Exo1 (K589E) polymorphism, G/A heterozygote, A/A homozygote, and combined G/A + A/A genotypes were found to be associated with 2.30-, 4.85-, and 3.04-fold higher risk of prostate cancer, respectively (odds ratio = 2.3021, 95% confidence interval = 2.956-4.0905, p = 0.0031; odds ratio = 4.8462, 95% confidence interval = 1.0198-23.0284, p = 0.0291; OR = 3.0362, 95% confidence interval = 1.7054-5.4053, p = 0.0001, respectively). The "A" allele showed significant association with increased susceptibility (2.29-fold) to prostate cancer (odds ratio = 2.2955, 95% confidence interval = 1.4529-3.6270, p = 0.0004). Our results suggest that CDH1 -160C/A and Exo1 K589E polymorphisms are associated with increased susceptibility to prostate cancer in Bangladeshi population.

Entities:  

Keywords:  Bangladesh; Prostate cancer; single-nucleotide polymorphism

Mesh:

Substances:

Year:  2019        PMID: 30880589     DOI: 10.1177/1010428319830837

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  6 in total

1.  Correlation of -160C > A and -347GA > G polymorphisms in E-cadherin gene and gastric cancer in north of Iran.

Authors:  Ramin Shekarriz; Reza Alikhani; Mohaddeseh Ghasemi; Reza Alizadeh Navaei; Mohammad Bagher Hashemi-Soteh
Journal:  J Res Med Sci       Date:  2021-01-28       Impact factor: 1.852

Review 2.  A review on the genetic polymorphisms and susceptibility of cancer patients in Bangladesh.

Authors:  Golap Babu; Shad Bin Islam; Md Asaduzzaman Khan
Journal:  Mol Biol Rep       Date:  2022-03-11       Impact factor: 2.742

3.  Identification of potential biomarkers and pivotal biological pathways for prostate cancer using bioinformatics analysis methods.

Authors:  Zihao He; Xiaolu Duan; Guohua Zeng
Journal:  PeerJ       Date:  2019-10-04       Impact factor: 2.984

4.  Identification of DNA Damage Repair-Associated Prognostic Biomarkers for Prostate Cancer Using Transcriptomic Data Analysis.

Authors:  Pai-Chi Teng; Shu-Pin Huang; Chia-Hsin Liu; Ting-Yi Lin; Yi-Chun Cho; Yo-Liang Lai; Shu-Chi Wang; Hsin-Chih Yeh; Chih-Pin Chuu; Deng-Neng Chen; Wei-Chung Cheng; Chia-Yang Li
Journal:  Int J Mol Sci       Date:  2021-10-29       Impact factor: 5.923

5.  Methylation and Polymorphism in CDH1 Gene Promoter Among Patients with Diffuse Gastric Cancer.

Authors:  Mohadeseh Naghi Vishteh; Mehrdad Zeinalian; Majid Kheirollahi; Amirreza Javadi Mamaghani; Mohammad Ali Zolfaghari; Aliyar Mirzapour; Meisam Barati; Seyed Javad Seyed Tabaei
Journal:  Int J Prev Med       Date:  2022-03-12

Review 6.  Comprehensive Studies of Different Cancer Diseases among Less-Developed Countries.

Authors:  Mohammed M Rahman; Firoz A D M Opo; Abdullah M Asiri
Journal:  Healthcare (Basel)       Date:  2022-02-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.